LPTX LEAP THERAPEUTICS INC Contract Awards 8-K Filing 2024 - Study Enrollment Complete Leap Therapeutics, Inc. announced the completion of enrollment in Part B of the DeFianCe Study for DKN-01, a treatment for colorectal cancer patients.Get access to all SEC 8-K filings of the LEAP THERAPEUTICS INC